Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Blogs about Biotechnology, Pharmaceutical and Healthcare

11:16 EDT 23rd April 2014 | BioPortfolio

Read the latest opinions - blogs from pharmaceutical and life science industry experts.

Showing News Articles 1–25 of 43,000+

Wednesday 23rd April 2014

April 22 Breakout Trend Day Breadth Update and Stock Scan

With price breaking through resistance and defying divergences, let’s take a look at Sector Breadth (what’s strong, what’s weak) along with the top trending stocks of the day.[More...]

Blocking the build-up of toxic free radicals in the brain could prevent Alzheimer’s disease

New insights into how harmful molecules accumulate in neurons could lead to novel drug interventions for the most common cause of dementia in older adults.

Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT

Results expected for Q3, 2014 April 23, 2014 Anergis, a company discovering and developing proprietary allergy vaccines, today announced that it has completed the enrolment of 196 subjects in the long-term efficacy trial of its birch pollen allergy vaccine AllerT, and expects to release results in the third quarter of 2014. The long-term efficacy trial […]

Celldex’s Phase 1 Study of CDX-1401 Published in Science Translational Medicine

First clinical study to demonstrate that an off-the-shelf vaccine targeting dendritic cells can safely lead to robust humoral and cellular immunity April 16, 2014 Celldex Therapeutics, Inc. announced today that final data from its Phase 1 study of CDX-1401 in solid tumors, including long-term patient follow-up, have been published in Science Translational Medicine (Vol 6 Issue 232). […]

GSK Acquires Novartis’ Global Vaccines Business for $5.25 Billion as Part Larger Reshuffle

GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders April 22, 2014 GlaxoSmithKline plc today announces a major 3-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses (the “Transaction”). In summary: GSK and Nova...

Collaboration and Medical Countermeasures: Furthering Regulatory Science

By: Dr. Stephen Ostroff “I hope no one ever needs these products,” isn’t something you hear too often, particularly from those developing drugs, biologics, or devices. That point of view—and a universal desire to protect the American public—is what sets … Continue reading →

Balancing the Prevention of Opioid Abuse and Appropriate Pain Management

By: Margaret A. Hamburg, M.D. Earlier today I had the opportunity to address the Rx Abuse Summit in Atlanta, Georgia, an important three day conference that brings together local, state and federal agencies, business, academia, clinicians, treatment providers, counselors, educators, … Continue reading →

Kala Pharma Grabs $22.5M More For Eye Drugs

In the big market for treatments for age-related macular degeneration, the leading cause of blindness in the elderly, there’s a turf war between companies with injectable drugs. Kala Pharmaceuticals is one of a few companies trying to bring an eye...

China Private Health Care Receives A Shot in the Arm From Chindex Deal

A consortium’s increased offer for the private hospital and medical equipment supplier bodes well for the expansion of private health care providers in China.

Fuzzy Laws Complicate Tighter Indian Online Pharmacy Rules

The Maharashtra FDA has been sued by a few online pharmacies that claimed to have followed proper procedures in shipping products for valid prescriptions. Under pressure from international agencies, the central regulatory agency is calling a meeting...

Sovaldi's Q1 Is A Home Run With Men On Base; Why Gilead May Triple From Here

ByDoctoRx:Background: I have written twice about Gilead Sciences (GILD). A few weeks ago I wrote A Physician-Businessman's Views Of Gilead, With Emphasis On Sovaldi, and after the stock price and other biotechs dropped, I followed up with Reevaluating Gilead Sciences After The Sell-Off. In the latter article, I indicated that since the news flow was actually positive but the stock was lower, I tho...

Bristol-Myers Squibb: Great Dividend Stocks From The Bond Refugee Screen - High Yields And Low Volatility Part VI

By Glyndon Park:Recently Citi Equity Research released an updated list of global bond refugee stocks. Stocks with higher dividends ands lower volatility as an alternative to bond investments. Among companies making the cut Bristol-Myers Squib (BMY) with a current dividend yield of 2.9%. Below we continue our bond refugee review with BMYPreviously Reviewed Bond Refugee StocksBond Refugee Recommend...

What do European doctors say about our guidelines for statins?

In November of last year the American Heart Association released to recommendations on who should be taking statins (drugs like Lipitor/atorvastatin), the most common medicines we use to control cholesterol levels. High cholesterol levels are associated with higher risk of heart attacks and strokes, and taking statins, which lower cholesterol, can reduce those risks. The [...]

Cougars’ diverse diet helped them survive extinction that killed saber-tooth, American lion

Cougars may have survived the mass extinction that took place […]

Global Drug Industry Does About-Face

After decades of broadening their drug portfolios through acquisitions, pharmaceutical companies are reversing course to focus more narrowly on what they think they can do best.

Tuesday 22nd April 2014

Lessons learned during an unplanned EMR downtime

A guest column by the American College of Physicians, exclusive to KevinMD.com. On a Thursday in April, my practice upgraded its electronic health record to the next version, the “latest and greatest” with more features, as well as compliance with meaningful uses 2 through infinity. That was the good news. The bad news was that it meant [...]

U.S. Appeals Court Rules Glenmark Owes Abbott $25 Million In Patent Case

A U.S. appeals court ruled against Glenmark Pharmaceuticals in a patent-infringement case involving the Tarka (trandolapril/verapamil) drug for treating hypertension made by Abbott Laboratories.

RAPS Taiwan Chapter Leads Way For Further Asian Expansion

The Regulatory Affairs Professionals Society has chosen the island ahead of other candidates to form its first chapter in Asia, as it expands its footprint in the region and around the world.

High Court Rules Against India Device Maker In Procurement Case

A high court in India’s financial hub of Mumbai ruled in favor of a state's interest in procuring coronary stents through a bidding system, rejecting a challenge by Vascular Concepts, which makes and imports the stents and other devices.

India DCGI Orders Probe Into Vietnam Ban On 'Substandard-Drug' Exports

The Drug Controller General of India said he has ordered an investigation of assertions by Vietnam that it had to ban imports from nearly four dozen India drug makers because of substandard products.

Financial Challenges for Non-Profit Hospitals; Lab Budget Reductions Anticipated

Hard times are coming for non-profit hospitals and, in my opinion, particularly for pathology and the clinical lab contained within them (see: Ratings Agencies Go Negative on Not-for-Profit Hospitals for 2014; Their Projections Signal Fewer Resources...

Top stories in health and medicine, April 23, 2014

From MedPage Today: Muscle Pain in the ED. Patients presenting to the emergency department with widespread muscle pain may have very low levels of vitamin D. Care of Cancer Survivors Often Falls Short. Most cancer patients enter survivorship with little direction from oncologists or primary care providers. MERS Cases Still Climbing. The number of cases of [...]

Amgen's CEO Discusses Q1 2014 Results - Earnings Call Transcript

Amgen, Inc. (AMGN) Q1 2014 Results Earnings Conference Call April 22, 2014 05:15 PM ET Executives Arvind Sood - VP of Investor Relations Bob Bradway - Chairman and CEO Michael Kelly - Interim CFO Tony Hooper - Head of Global Commercial Operations Sean Harper - Head of R&D Analysts Matt Roden - UBS Terrence Flynn - Goldman Sachs Matthew Harrison - Morgan Stanley Eric Schmidt - Cowen an...

Intuitive Surgical's CEO Discusses Q1 2014 Results - Earnings Call Transcript

Start Time: 16:37 End Time: 17:34 Intuitive Surgical, Inc. (ISRG) Q1 2014 Earnings Conference Call April 22, 2014 04:30 PM ET Executives Gary Guthart - President and CEO Marshall Mohr - SVP and CFO Patrick Clingan - Director of Finance Calvin Darling - Director, FP&A and IR Analysts Ben Andrew - William Blair & Company Tycho Peterson - JPMorgan Robert Hopkins - Bank of America-Merr...

Illumina's CEO Discusses Q1 2014 Results - Earnings Call Transcript

Illumina, Inc. (ILMN) Q1 2014 Earnings Conference Call April 22, 2014 5:00 PM ET Executives Rebecca Chambers – Senior Director, IR Jay Flatley – CEO Marc Stapley – SVP and CFO Analysts Tycho Peterson – JPMorgan Doug Schenkel – Cowen & Company Derik De Bruin – Bank of America Dan Leonard – Leerink Ross Muken – ISI Group Amanda Murphy – William Blair Isaac Ro – Gold...


Search BioPortfolio: